Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 2015
|
| In: |
The lancet. Oncology
Year: 2015, Volume: 16, Issue: 16, Pages: 1700-1710 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(15)00373-3 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/S1470-2045(15)00373-3
|
| Author Notes: | Javier Cortés, Véronique Dieras, Jungsil Ro, Jérôme Barriere, Thomas Bachelot, Sara Hurvitz, Emilie Le Rhun, Marc Espié, Sung-Bae Kim, Andreas Schneeweiss, Joo Hyuk Sohn, Jean-Marc Nabholtz, Pirkko-Liisa Kellokumpu-Lehtinen, Julie Taguchi, Federico Piacentini, Eva Ciruelos, Petri Bono, Mahmoud Ould-Kaci, Flavien Roux, Heikki Joensuu |
| Item Description: | Gesehen am 01.08.2016 |
|---|---|
| Physical Description: | Online Resource |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(15)00373-3 |